scholarly journals CD73 expression in normal, hyperplastic, and neoplastic thyroid: a systematic evaluation revealing CD73 overexpression as a feature of papillary carcinomas

2021 ◽  
Author(s):  
Inês Monteiro ◽  
Edoardo Missiaglia ◽  
Amedeo Sciarra ◽  
João Vasco Santos ◽  
Justine Bouilly ◽  
...  
Keyword(s):  
Mrna Expression ◽  
Systematic Evaluation ◽  
Papillary Thyroid ◽  
Intense Staining ◽  
Normal Thyroid ◽  
Thyroid Carcinomas ◽  
Mrna Profiling ◽  
Thyroid Goiter ◽  
Poorly Differentiated ◽  
Cd73 Expression

AbstractCD73 converts AMP to adenosine, an immunosuppressive metabolite that promotes tumorigenesis. This study presents a systematic evaluation of CD73 expression in benign, hyperplastic, and neoplastic thyroid. CD73 expression was assessed by immunohistochemistry in 142 thyroid samples. CD73 was expressed in normal thyroid (3/6) and goiter (5/6), with an apical pattern and mild intensity. Apical and mild CD73 expression was also present in oncocytic cell adenomas/carcinomas (9/10; 5/8) and in follicular adenomas/carcinomas (12/18; 23/27). In contrast, papillary thyroid carcinomas featured extensive and intense CD73 staining (49/50) (vs. normal thyroid/goiter, p < 0.001). Seven of nine anaplastic carcinomas were CD73-positive with heterogeneous extensiveness of staining. Medullary and poorly differentiated carcinomas were mostly CD73-negative (1/6; 2/2). These results were corroborated by NT5E mRNA profiling. Papillary carcinomas feature enhanced CD73 protein and mRNA expression with distinct and intense staining, more pronounced in the invasive fronts of the tumors.

ERK Phosphorylation Is Not Increased in Papillary Thyroid Carcinomas with BRAFV600EMutation Compared to That of Corresponding Normal Thyroid Tissues

2013 ◽  
Vol 38 (2) ◽  
pp. 89-97 ◽  
Author(s):  
Sun Wook Kim ◽  
Hee Kyung Kim ◽  
Ji In Lee ◽  
Hye Won Jang ◽  
Jun-Ho Choe ◽  
...  
Keyword(s):  
Papillary Thyroid ◽  
Normal Thyroid ◽  
Thyroid Carcinomas ◽  
Erk Phosphorylation

scholarly journals MON-500 Cell Adhesion Molecules mRNA Expression in Thyroid Tumors

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Larissa Teodoro ◽  
Karina Colombera Peres ◽  
Matheus Nascimento ◽  
Elisangela Souza Teixeira ◽  
Icleia Siqueira Barreto ◽  
...  
Keyword(s):  
Gene Expression ◽  
Cell Adhesion ◽  
Mrna Expression ◽  
Adhesion Molecules ◽  
Cell Adhesion Molecules ◽  
Cancer Biology ◽  
Thyroid Nodules ◽  
Thyroid Tumors ◽  
Papillary Thyroid ◽  
Thyroid Carcinomas

Abstract Thyroid cancer biology is extremely diverse. While some cases never progress clinically or do so indolently, others evolve aggressively and may even lead to death. Cell adhesion molecules are glycoproteins present in the cell membrane and play an important role in inflammatory and neoplastic diseases by recruiting immune cells to these sites. The aim of the present study was to investigate the role of mRNA expression of SELL, ICAM1 and ITGAL in thyroid tumors and their relationship with lymphocyte infiltration. We evaluated by RT-qPCR technique 191 thyroid nodules including 97 benign (79 females, 17 males; 49.8±12.5 years old) and 94 malignant (71 females, 23 males; 48.3±15.5years old) cases. Clinical and pathology data were obtained from 47 goiters; 50 follicular adenomas (FA); 74 papillary thyroid carcinomas (PTC), including: 29 classic papillary thyroid carcinomas (CPTC), 21 follicular variant of PTC (FVPTC), 12oxifilic variant of PTC (OVPTC), 12 tall cell papillary thyroid carcinomas (TCPTC); and 20 follicular thyroid carcinomas (FTC). All patients were managed according to a standard protocol based on current guidelines and followed-up for 78.7±54.2 months. SELL was more expressed in malignant (0.85±1.54 UA) than in benign (0.54±0.71 UA, p=0.0027) nodules. The same occurred with ICAM1 (0.99±1.41 vs. 0.46±0.85, p=0.0001), but not with ITGAL gene expression (1.04±1.63 vs. 0.76±1.21, p=0.2131). In addition, the expression of SELL was different when we compared PTC with FA (0.94±1.62 UA vs. 0.47±0.72 UA, p=0.0018) and FTC with FA (0.82±2.38 UA vs. 0.47±0.72 UA, p=0.0078). ICAM1 expression was lower in goiters (0.46±0.90 UA) when compared with PTC (0.93±1.22 UA, p=0.0030) and FTC (1.03±3.30 UA, p=0.0207). Higher expression of ICAM1 (1.16±3.04 UA vs. 0.52±0.96 UA, p=0.0064) and ITGAL (1.17±1.54 UA vs. 0.49±1.39 UA, p=0.0244) was observed in tumors with lymphocyte infiltrate. Also, ITGAL gene expression was higher in tumors that had distant metastasis at diagnosis (1.53±2.18 UA vs. 0.57±1.10 UA, p=0.0217). We were not able to demonstrate any association between any of the investigated molecules and patients’ outcome. In conclusion, our data suggest that cell adhesion molecules may play an important role in neoplastic thyroid cells proliferation. In addition, our findings show that gene expression of SELL and ICAM1 may assist in the histological characterization of follicular patterned thyroid nodules.

Papillary carcinoma in a thyroglossal duct remnant with normal thyroid gland

1993 ◽  
Vol 107 (12) ◽  
pp. 1174-1176 ◽  
Author(s):  
Kadriye Yildiz ◽  
Haydar Köksal ◽  
Yavuz Özoran ◽  
Hayrettin Muhtar ◽  
Münir Telatar
Keyword(s):  
Thyroid Gland ◽  
Papillary Carcinoma ◽  
Papillary Thyroid ◽  
Thyroglossal Duct ◽  
Normal Thyroid ◽  
Thyroid Carcinomas ◽  
First Report ◽  
Thyroglossal Duct Remnant

Carcinoma in the thyroglossal duct remnant is relatively uncommon. Since the first report by Uchermann (1915), more than 150 cases of carcinoma have been reported, and the majority have been papillary thyroid carcinomas (Li Volsi etal., 1974; McNicol etal., 1988). In this report, we present a case of papillary carcinoma in the thyroglossal duct with a normal thyroid gland

A subset of papillary thyroid carcinomas containKRASmutant subpopulations at levels above normal thyroid

2012 ◽  
Vol 53 (2) ◽  
pp. 159-167 ◽  
Author(s):  
Meagan B. Myers ◽  
Karen L. McKim ◽  
Barbara L. Parsons
Keyword(s):  
Papillary Thyroid ◽  
Normal Thyroid ◽  
Thyroid Carcinomas

scholarly journals BRAF Mutations in Papillary Thyroid Carcinomas Inhibit Genes Involved in Iodine Metabolism

2007 ◽  
Vol 92 (7) ◽  
pp. 2840-2843 ◽  
Author(s):  
C. Durante ◽  
E. Puxeddu ◽  
E. Ferretti ◽  
R. Morisi ◽  
S. Moretti ◽  
...  
Keyword(s):  
Glucose Transporter ◽  
Thyroid Tissue ◽  
Braf V600e ◽  
Mrna Levels ◽  
Papillary Thyroid ◽  
Sodium Iodide Symporter ◽  
Braf Mutations ◽  
Normal Thyroid ◽  
Thyroid Carcinomas ◽  
Iodine Metabolism

Abstract Context: BRAF mutations are common in papillary thyroid carcinomas (PTCs). By affecting the expression of genes critically related to the development and differentiation of thyroid cancer, they may influence the prognosis of these tumors. Objective: Our objective was to characterize the expression of thyroid-specific genes associated with BRAF mutation in PTCs. Design/Setting and Patients: We examined the expression of key markers of thyrocyte differentiation in 56 PTCs with BRAF mutations (BRAF-mut) and 37 with wild-type BRAF (BRAF-wt). Eight samples of normal thyroid tissue were analyzed as controls. Quantitative PCR was used to measure mRNA levels for the sodium/iodide symporter (NIS), apical iodide transporter (AIT-B), thyroglobulin (Tg), thyroperoxidase (TPO), TSH receptor (TSH-R), the transcription factor PAX8, and glucose transporter type 1 (Glut1). NIS protein expression and localization was also analyzed by immunohistochemistry. Results: mRNA levels for all thyroid-specific genes were reduced in all PTCs vs. normal thyroid tissues. NIS, AIT-B, Tg, and TPO expression was significantly lower in BRAF-mut tumors than in the BRAF-wt group. Glut-1 transcript levels were increased in all PTCs, and additional increases were noted in BRAF-mut tumors. In both tumor subsets, the NIS protein that was expressed was abnormally retained in the cytoplasm. Conclusion: BRAF V600E mutation in PTCs is associated with reduced expression of key genes involved in iodine metabolism. This effect may alter the effectiveness of diagnostic and/or therapeutic use of radioiodine in BRAF-mut PTCs.

scholarly journals MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights

2014 ◽  
Vol 52 (2) ◽  
pp. 181-189 ◽  
Author(s):  
Matthias S Dettmer ◽  
Aurel Perren ◽  
Holger Moch ◽  
Paul Komminoth ◽  
Yuri E Nikiforov ◽  
...  
Keyword(s):  
Mirna Expression ◽  
Thyroid Tissue ◽  
Mirna Expression Profile ◽  
Normal Thyroid ◽  
Thyroid Carcinomas ◽  
Microrna Profile ◽  
Poorly Differentiated ◽  
The Difference ◽  
Well Differentiated ◽  
Differentiated Thyroid Cancers

The diagnosis of conventional and oncocytic poorly differentiated (oPD) thyroid carcinomas is difficult. The aim of this study is to characterise their largely unknown miRNA expression profile and to compare it with well-differentiated thyroid tumours, as well as to identify miRNAs which could potentially serve as diagnostic and prognostic markers. A total of 14 poorly differentiated (PD), 13 oPD, 72 well-differentiated thyroid carcinomas and eight normal thyroid specimens were studied for the expression of 768 miRNAs using PCR-Microarrays. MiRNA expression was different between PD and oPD thyroid carcinomas, demonstrating individual clusters on the clustering analysis. Both tumour types showed upregulation of miR-125a-5p, -15a-3p, -182, -183-3p, -222, -222-5p, and downregulation of miR-130b, -139-5p, -150, -193a-5p, -219-5p, -23b, -451, -455-3p and of miR-886-3p as compared with normal thyroid tissue. In addition, the oPD thyroid carcinomas demonstrated upregulation of miR-221 and miR-885-5p. The difference in expression was also observed between miRNA expression in PD and well-differentiated tumours. The CHAID algorithm allowed the separation of PD from well-differentiated thyroid carcinomas with 73–79% accuracy using miR-23b and miR-150 as a separator. Kaplan–Meier and multivariate analysis showed a significant association with tumour relapses (for miR-23b) and with tumour-specific death (for miR-150) in PD and oPD thyroid carcinomas. MiRNA expression is different in conventional and oPD thyroid carcinomas in comparison with well-differentiated thyroid cancers and can be used for discrimination between these tumour types. The newly identified deregulated miRNAs (miR-150, miR-23b) bear the potential to be used in a clinical setting, delivering prognostic and diagnostic informations.

scholarly journals TERT mRNA Expression as a Novel Prognostic Marker in Papillary Thyroid Carcinomas

Thyroid ◽  
2019 ◽  
Vol 29 (8) ◽  
pp. 1105-1114 ◽  
Author(s):  
Aya Tanaka ◽  
Michiko Matsuse ◽  
Vladimir Saenko ◽  
Tomoe Nakao ◽  
Kosho Yamanouchi ◽  
...  
Keyword(s):  
Mrna Expression ◽  
Prognostic Marker ◽  
Papillary Thyroid ◽  
Thyroid Carcinomas

scholarly journals Aberrant Expression of Androgen Receptor Associated with High Cancer Risk and Extrathyroidal Extension in Papillary Thyroid Carcinoma

Cancers ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 1109 ◽  
Author(s):  
Chen-Kai Chou ◽  
Shun-Yu Chi ◽  
Fong-Fu Chou ◽  
Shun-Chen Huang ◽  
Jia-He Wang ◽  
...  
Keyword(s):  
Gene Expression ◽  
Cell Migration ◽  
Androgen Receptor ◽  
Papillary Thyroid Carcinoma ◽  
Mrna Expression ◽  
Thyroid Tissue ◽  
Extrathyroidal Extension ◽  
Papillary Thyroid ◽  
Normal Thyroid Tissue ◽  
Normal Thyroid

Male gender is a risk factor for mortality in patients with papillary thyroid carcinoma (PTC). This study investigated the impact of androgen receptor (AR) gene expression on the clinical features and progression of PTC. The levels of AR mRNA and protein in frozen, formalin-fixed, paraffin-embedded tissue samples from PTC and adjacent normal thyroid tissue were assessed by quantitative real-time polymerase chain reaction and immunohistochemical staining, respectively, and the relationships between AR expression and clinical features were analyzed. The thyroid cancer cell lines, BCPAP and TPC-1, were used to evaluate the effects of AR on the regulation of cell migration, and key epithelial–mesenchymal transition (EMT) markers. AR mRNA expression was significantly higher in normal thyroid tissue from men than women. The sex difference in AR mRNA expression diminished during PTC tumorigenesis, as AR mRNA expression levels were lower in PTC than normal thyroid tissues from both men and women. AR mRNA expression was significantly decreased in PTC patients with higher risk and in those with extrathyroidal extension. Overexpression of AR in BCPAP cells decreased cell migration and repressed the EMT process by down-regulating mRNA expression of N-cadherin, Snail1, Snail2, Vimentin, and TWIST1 and up-regulating E-cadherin gene expression. These results suggest that suppression of the androgen–AR axis may lead to aggressive tumor behavior in patients with PTC.

Sign in / Sign up

Export Citation Format

Share Document